RANI THERAPEUTICS HOLDINGS, INC. financials

RANI CIK 0001856725

Source: EDGAR filings · Built 2026-06-02T03:54:29Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Free Cash Flow -18.80M -35.76M -52.47M -48.13M -32.75M -16.16M
EBITDA -37.41M -52.29M -65.28M -62.90M -51.10M -15.96M
Working Capital 40.65M 9.85M 42.86M 96.11M 116.95M 69.64M
Net Debt -14.30M 26.33M 24.85M 4.06M -117.45M -69.29M
Operating Margin -2345.99% -5186.19% -1899.12% -3580.95%
Net Margin -1817.09% -2920.04% -306.63% -3615.37%
Return on Equity (ROE) -89.89% -1506.93% -264.03% -83.00% -17.57% 14.74%
Return on Assets (ROA) -50.62% -81.94% -58.65% -28.32% -6.71% -21.03%
Current Ratio 4.21× 1.50× 6.36× 20.96× 45.30× 14.12×
Debt-to-Equity 0.13× 15.11× 2.39× 0.84× 0.00× -0.03×
Effective Tax Rate 0.00% -0.11% -0.08% -0.21%
Cash Conversion Ratio 0.63× 1.18× 1.51× 1.52× 3.87× 0.90×
Accruals Ratio -0.19× 0.15× 0.30× 0.15× 0.19× -0.02×
SBC % of Revenue 722.47% 1559.44% 831.62% 0.00%
CapEx Coverage -212.66× -132.45× -41.69× -28.73× -63.73× -12.47×
Free Cash Flow Per Share $-0.28 $-1.26 $-2.06 $-2.02 $-1.68

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
P/S 54.68× 37.95× 117.55×
P/B 2.70× 19.58× 6.58× 3.81× 6.74×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Revenue from Contract with Customer, Excluding Assessed Tax 1.63M 1.03M 0 0 2.72M 462.00K
Research and Development Expense 20.20M 26.68M 39.62M 36.61M 26.48M 12.04M
Operating Expenses 39.94M 54.34M 66.10M 63.45M 54.32M -17.01M
Operating Income (Loss) -38.31M -53.31M -66.10M -63.45M -51.60M -16.54M
Income Tax Expense (Benefit) 0 0 0 70.00K 41.00K 35.00K
Net Income (Loss) Attributable to Parent -29.67M -30.02M -33.97M -30.59M -8.33M
Earnings Per Share, Basic $-0.45 $-1.05 $-1.33 $-1.28 $-0.43
Weighted Average Number of Shares Outstanding, Basic 66.14M 28.48M 25.50M 23.82M 19.53M
Earnings Per Share, Diluted $-0.45 $-1.05 $-1.33 $-1.28 $-0.43
Weighted Average Number of Shares Outstanding, Diluted 66.14M 28.48M 25.50M 23.82M 19.53M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Cash and Cash Equivalents, at Carrying Value 18.62M 3.76M 5.86M 27.01M 117.45M 73.06M
Assets, Current 53.32M 29.74M 50.85M 100.92M 119.59M 74.94M
Assets 58.62M 36.63M 57.92M 108.03M 124.21M 79.42M
Long-term Debt 25.00M 30.00M 30.00M
Liabilities, Current 12.67M 19.89M 7.99M 4.82M 2.64M 5.31M
Long-term Debt, Excluding Current Maturities 0 9.61M 24.48M 29.15M 0 2.41M
Liabilities 17.11M 33.14M 32.47M 34.02M 2.64M 8.04M
Stockholders' Equity Attributable to Parent 33.01M 1.99M 12.87M 36.85M 47.41M -113.34M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2021
Net Cash Provided by (Used in) Operating Activities -18.71M -35.50M -51.24M -46.52M -32.24M -14.96M
Payments to Acquire Property, Plant, and Equipment 88.00K 268.00K 1.23M 1.62M 506.00K 1.20M
Net Cash Provided by (Used in) Investing Activities -7.03M 19.81M 29.86M -72.44M -506.00K -1.20M
Net Cash Provided by (Used in) Financing Activities 40.30M 13.59M 233.00K 29.00M 77.15M 72.68M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RANI CIK 0001856725), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

GT

THE GOODYEAR TIRE & RUBBER COMPANY

QNCX

Quince Therapeutics, Inc.

ARE

ALEXANDRIA REAL ESTATE EQUITIES, INC.